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The overall effect of brain zinc (Zn
2+) in the progression and development of Alzheimer’s disease (AD) is still not completely
understood. Although an excess of Zn
2+ can exacerbate the pathological features of AD, a deﬁcit of Zn
2þ intake has also been
shown to increase the volume of amyloid plaques in AD transgenic mice. In this study, we investigated the effect of dietary Zn
2þ
supplementation (30p.p.m.) in a transgenic mouse model of AD, the 3xTg-AD, that expresses both b amyloid (Ab)- and
tau-dependent pathology. We found that Zn
2+ supplementation greatly delays hippocampal-dependent memory deﬁcits and strongly
reduces both Ab and tau pathology in the hippocampus. We also evaluated signs of mitochondrial dysfunction and found that
Zn
2+supplementation preventsthe age-dependentrespiratory deﬁcitsweobservedinuntreated 3xTg-ADmice.Finally,wefound
that Zn
2+ supplementation greatly increases the levels of brain-derived neurotrophic factor (BDNF) of treated 3xTg-AD mice.
In summary, our data support the idea that controlling the brain Zn
2þ homeostasis may be beneﬁcial in the treatment of AD.
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Alzheimer’s disease (AD) is the most common form of
dementia and is characterized by the accumulation of
amyloid-b peptide (Ab) and the formation of neuroﬁbrillary
tangles made of hyperphosphorylated tau (h-tau). The
pathogenic role of metal dyshomeostasis in AD has been
largely debated in recent years.
1 Ab aggregation is, in fact, a
process strongly potentiated by the peptide interaction with
several metals and zinc (Zn
2þ), in particular.
2 In addition, at
high concentrations (250mM), Zn
2þ has been shown to
trigger tau phosphorylation as well as its ﬁbrillization.
3,4
However, the effect of Zn
2þ on tau phosphorylation appears




cells by blocking ion ﬂuxes through Ab-induced cation
permeable channels
5 or competes with Cu
2þ in its binding
to Ab, thereby inhibiting amyloid plaque formation.
6
Zn
2þ is sequestered into the mitochondria
7,8 and mito-
chondrial dysfunctions as well as energy deﬁciency are also
prominentearlyeventsinAD.
9Furthermore,recentﬁndingsin
a triple transgenic mouse model of AD indicate a synergistic
interaction between Ab and h-tau in impairing the oxidative
phosphorylation system (OXPHOS) as well as the production
of reactive oxygen species.
9 In that respect, we have also
previously shown the expression of pro-AD factors, such as
mutant human presenilin-1 (PS1), amyloid precursor protein
(APP) and human h-tau present in 3xTg-AD mice strongly
alters intracellular Zn
2þ homeostasis in cultured cortical
neurons undergoing oxidative stress.
10
Although it seems clear that alterations in the content of
brain Zn
2þ canhave apathogenic roleinAD,
2,11there are still
conﬂicting results about how the overall brain bioavailability of
the cation can affect the disease progression. On one
hand, several key studies have demonstrated that the use of
Zn
2þ-binding compounds such as clioquinol or PBT2 restore
Zn
2þ homeostasis, greatly reduces Ab pathology and
protects against cognitive decline in transgenic AD
models.
12,13 On the other hand, a recent study, in an AD
mouse model,
14 has shown that dietary Zn
2þ supplementa-
tion exacerbates cognitive deﬁcits but surprisingly decreases
amyloid deposits. Furthermore, Zn
2þ depletion has been
found to increase the volume of amyloid plaques
15 and data
obtained in transgenic mice genetically depleted of synaptic
Zn
2þ, ZnT3-KO mice, indicate that such depletion leads to an
age-dependent decline of cognitive functions.
16 Moreover,
lactational zinc deﬁciency has been shown to promote
apoptotic neuronal loss in the mouse hippocampus.
17
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www.nature.com/cddisNeurotrophic signaling pathways are also deregulated in
AD.
18 In particular, recent studies have shown that decrease
levels of brain-derived neurotrophic factor (BDNF) correlate
with the severity of AD-related cognitive impairment,
19
suggesting that reduced BDNF availability may be an early
cofactor involved in AD development. Interestingly, Zn
2þ has
been shown to be an important modulator of this pathway as
the cation facilitates the maturation of BDNF from pro-BDNF




In this study, we investigated the effect of dietary Zn
2þ
supplementation on the disease progression of the 3xTg-AD
mouse, a transgenic animal model of AD that exhibits both
Ab- and tau-dependent pathology. Zn
2þ supplementation
was started early on in male animals at 1 month of age
(m.o.a.) testing the hypothesis that such early exposure to the
cation can set in motion a better intraneuronal Zn
2þ homeo-
stasis and counteract the aging-related Zn
2þ deregulation
that has been associated with AD.
2 End points of the study
were analysis of cognitive decline, the appearance of
intraneuronal Ab and h-tau, AD-related mitochondrial
dysfunctions, as well as disruption of the BDNF neurotrophic
pathway.
Results
Dietary zinc supplementation counteracts the
development of hippocampus-dependent cognitive
deﬁcits in 3xTg-AD mice. To evaluate the role of Zn
2þ
supplementation in 3xTg-AD mice, 1-month-old male
animals (n¼9) were treated with 30p.p.m. of ZnSO4 for
11–13 months. PS1-KI mice (n¼11) that do not develop Ab
or tau pathology nor show any cognitive deﬁcits were used as
control animals.
21 At the end of the treatment, mice were
assessed for both hippocampus- and cortex-dependent
cognitive tasks. Mice were ﬁrst studied for their
performance on the morris water maze (MWM) test, a task
that is highly dependent on the hippocampus, to investigate
spatial memory functioning. At ﬁrst, we assessed the integrity
of the mice learning process and found no differences in task
acquisition (data not shown), indicating that, during a 3-day
period of training, all groups learned equally well how to ﬁnd
the submerged platform using intra- and extra-maze visible
cues. After the last training trial, spatial reference memory
probe trials were conducted at 1.5 and 24h to examine
short- and long-term memory, respectively. As previously
reported,
21 3xTg-AD mice displayed no impairment in short-
term memory, while they manifested long-term memory
deﬁcits as indicated by the statistically signiﬁcant increase in
the time spent to ﬁnd the platform (control versus 3xTg-AD;
(P¼0.010)). We also observed (even though it was found to
be not statistically signiﬁcant, P¼0.083), a trend toward
decreased number of platform crosses (Figure 1a and b).
Interestingly, Zn
2þ treatment prevented the long-term
memory decline in 3xTg-AD mice as indicated by key
MWM parameters such as the latency to ﬁnd the platform
and the number of platform crosses that were basically
identical to the ones shown by disease-free PS1-KI mice
((Figure 1a and b); 3xTg-AD versus 3xTg-ADþZn
2þ,
P¼0.011). We next evaluated the effect of Zn
2þ
supplementation on the novel object recognition (NOR)
test, a cortex-dependent contextual task which relies on the
animal preference to explore a novel object over a familiar
object.
22–24 Analysis of the NOR performance showed no
differences between treated and untreated 3xTg-AD mice
(Figure 1c; (P¼0.669)) indicating that the beneﬁcial effects
of Zn
2þ were region-speciﬁc and restricted to the
hippocampus.
Zinc supplementation reduces intraneuronal Ab and tau
pathology in the hippocampus of 3xTg-AD mice. After
the cognitive evaluation, mice were killed and neuropathology
assessed to elucidate the underlying mechanisms by which
Zn
2þ feeding had improved cognition. 3xTg-AD mice develop
a progressive intraneuronal Ab accumulation in AD-relevant
Figure 1 Zn
2þ supplementation prevents the development of hippocampus-
dependent memorydeﬁcits in 3xTg-AD mice.Male 3xTg-AD micewere treated with
either water containing 30p.p.m. of ZnSO4 (n¼9) or tap water (n¼11) for 11–13
monthsand tested for the spatialmemoryversion of the MWM. (a and b) Micewere
givenamemoryprobetrialwherein,theplatformwasremoved1.5and24hafterthe
last training trial. Compared with untreated 3xTg-AD mice, Zn
2þ-fed 3xTg-AD mice
do not show any signiﬁcant difference in their MWM performanceat 1.5h. (a) When
tested at 24h, mice exhibit a marked decrease in the time (latency) they employed
to reach the point where the platform used to be. (b)Z n
2þ-treated 3xTg-AD mice
make also more platform crosses, even though such parameter does not reach
statistical signiﬁcance. (c)Z n
2þ treatment does not affect the performance of the
cortex-dependent novel object recognition test as treated and untreated 3xTg-AD
mice show no differences in their ability to remember an object to which they were
exposed 24h before. Error bars indicate mean values±S.E.M.; *Po0.05
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Cell Death and Diseaseregions such as the cerebral cortex and the hippo-
campus starting at 4m.o.a.
25 To determine whether Zn
2þ
supplementation can decrease the brain Ab load, immuno-
histochemistry was performed with the anti-Ab DE2B4 primary
antibody and results of this assay show a signiﬁcant decrease
in the hippocampus (Figure 2a–e; (P¼0.013)), but not in
the cortex of treated 3xTg-AD mice (see supplementary
Figure 1a and b), a ﬁnding that matches their behavioral
performance.
At about 12m.o.a., 3xTg-AD mice also show extensive
neuroﬁbrillary tangles, ﬁrst in the hippocampus (in particular
within pyramidal neurons of the CA1 subﬁeld) and then in the
cortex.
25 To investigate the effect of our Zn
2þ treatment on
the development of tau pathology, we employed an anti-tau
AT180 primary antibody that speciﬁcally detects tau phos-
phorylation at the thr231/ser235 site. As expected, we found
diffuse h-tau immunoreactivity in the CA1 subﬁeld and cortex
of untreated 3xTg-AD mice (Figure 2f and g). Interestingly,
Zn
2þ treatment produced a marked decrease of h-tau
immunoreactivity in the 3xTg-AD CA1 subﬁeld (Figure 2h–j;
(P¼0.010)) but not in the cortex (see supplementary Figure
1c and d), further indicating that Zn
2þ supplementation has a
potent region-speciﬁc effect on tau pathology.
Zinc supplementation restores mitochondrial function in
3xTg-AD mice. Mitochondrial dysfunctions have a pivotal
role in AD
9 and a previous study in 3xTg-AD mice has shown
that such deﬁcits are developed at early stages and precede
the manifestation of amyloid- and tau-dependent
pathology.
26 To investigate the effect of our Zn
2þ treatment
on AD-related mitochondrial deﬁcits, we investigated the
activity of mitochondrial complexes by employing a
combination of blue-native polyacrylamide gel electro-
phoresis (BN-PAGE) and subsequent histochemical in-gel
staining. As ﬁrst, to evaluate a potential age-dependent
decline in mitochondrial respiration, we studied the activity of
mitochondrial complexes I, II and IV obtained from
homogenates of the cortex, hippocampus and cerebellum
of 3xTg-AD mice at 2, 6 and 12–14m.o.a. These activities
were compared with age-matched PS1-KI mice. In the case
Figure 2 Zn
2þ supplementation reduces bothAb andtau pathologyin thehippocampusof 3xTg-ADmice. Immunohistochemistrywith speciﬁcantibodieswas employed
to detect deposits of intraneuronal Ab (a–d) and h-tau (f–j) in brain slices from treated and untreated 3xTg-AD mice (left column: 20  magniﬁcation; right column:
40  magniﬁcation).Comparedwithuntreatedmice(aandb),DABstainingshowsasigniﬁcantdecreaseofintraneuronalAbdepositsinthehippocampusoftreated3xTg-AD
mice (c and d). (b and d)4 0  magniﬁcation of the hippocampal CA1 area as shown in the rectangle. (e) Quantiﬁcation of Ab load as shown in a and c. Compared with
untreated mice (f, g), DAB staining shows a strong decrease of intraneuronal h-tau immunoreactivity in the hippocampus of Zn
2þ-fed 3xTg-AD mice (h and i). (g and i)
40  magniﬁcation of the CA1 area as shown in the rectangle. (j) Quantiﬁcation of h-tau levels from f and h. Error bars indicate mean values±S.E.M.; *Po0.05
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Cell Death and Diseaseof experiments with mice at 2 and 6m.o.a., we employed a
pool of three–ﬁve animals for each age group and each
genotype. We then compared the activities of these
mitochondrial complexes in treated and untreated 3xTg-AD
mice at 12–14m.o.a.
Hippocampus. When comparing 3xTg-AD with control mice,
we conﬁrmed the impairment in mitochondrial function
described by Yao et al.
26 and found an age-dependent
decay in the activity of mitochondrial complexes I and IV
starting at 6m.o.a. (Figure 3a–c; (control versus 3xTg-AD:
Complex I, P¼0.010; Complex II, P¼0.048; Complex IV,
Po o0.01)). Changes in enzyme activities were not
dependent on changes in protein expression (data not
shown). Zn
2þ-supplemented 3xTg-AD mice at 12–14m.o.a.
showed a complete recovery of all these defective respiratory
Figure 3 Zn
2þ supplementation rescues AD-related mitochondria deﬁcits in 3xTg-AD mice. BN-PAGE was employed to assess the activity of mitochondrial complexes I
(a, d and g), II (b, e and h) and IV (c, f and i) in isolated mitochondria obtained from the hippocampus (a–c), cerebral cortex (d–f), or the cerebellum (g–i) of treated and
untreated 3xTg-AD, as well as control mice at 2, 6 and 12–14m.o.a. When compared with age-matched untreated mice, functioning of mitochondrial complexes I and IV
appearsto bedecreasedinthehippocampus ofuntreated6-month-old3xTg-ADmice(aandc). Thesamedeﬁcitsarefound inhippocampalmitochondria of3xTg-ADmiceat
12–14m.o.a.; however, Zn
2þ supplementation completely counteracts the development of these deﬁcits (a–c). When comparing complex activities of cortical mitochondria
obtainedfrom6-month-old3xTg-ADversusage-matchedcontrolmice,complexesIandIVarefoundnotcompromised(d–f)whileastatisticallysigniﬁcantdeﬁcitisobservedin
thecase of complex II (e). Still in the cortex,complexesI and IV functioningis greatly compromised in untreated 3xTg-ADmice at 12–14m.o.a.and Zn
2þ treatmentis able to
completely rescue the deﬁcits (d–f). No changes are found in the cerebellum of 3xTg-AD mice compared with age-matched controls (g–i). *Po0.05; **Po0.01. Error bars
indicate mean values±S.E.M.
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Cell Death and Diseasecomplexes (Figure 3a–c; (3xTg-AD versus 3xTg-ADþZn
2þ:
Complex I, P¼0.008; Complex II, P¼0.001; Complex IV,
Po o0.01)).
Cortex. In contrast to what was found in the hippocampus,
compared with control mice 3xTg-AD animals showed no
deﬁcits at 2 and 6m.o.a., except for the complex II at 6m.o.a.
(P¼0.005). Moreover, activities of complexes I and IV were
also dramatically reduced at 14m.o.a. (control versus
3xTg-AD: Complex I, Po o0.01; Complex IV, P¼0.047).
Notably, Zn
2þ-supplemented 3xTg-AD mice at 12–14m.o.a.
showed a complete recovery in the activity of both complexes
I and IV (Figure 3d–f; (3xTg-AD versus 3xTg-ADþZn
2þ:
Complex I, Po o0.01; Complex IV, P¼0.045)).
Cerebellum. To test whether the mitochondrial deﬁcits
observed in the cortex and hippocampus were due to
AD-related mechanisms triggered by the expression of
mutant APP, PS1 and h-tau, we also analyzed the activity
of complexes I, II and IV in the cerebellum, a region that
shows no Ab- or tau-dependent pathology and is not affected
by AD. As expected, mitochondrial respiratory activities of all
the complexes showed a not statistically signiﬁcant age-
dependent decline in 3xtg-AD mice, compared with control
mice (Figure 3g–i).
Dietary zinc supplementation increases BDNF levels
in 3xTg-AD brains through MMPs activation. BDNF
signaling pathway is downregulated in AD,
18 and Zn
2þ has
been described to potently stimulate the maturation of BDNF
from inactive pro-BDNF via MMP activation.
20 We hence
employed gelatine zymography assay in order to investigate
the effect of Zn
2þ supplementation on the activation of
gelatine-degrading MMP-2 and MMP-9 in treated and
untreated 3xTg-AD mice brains. As shown in Figure 4a,
Zn
2þ treatment potently increased both MMP-2 and MMP-9
activity compared with untreated 3xTg-AD mice (P¼0.004
and P¼0.001, respectively). Finally, we evaluated the effect
of Zn
2þ supplementation on cerebral BDNF levels by
performing immunoblotting assay on treated and untreated
3xTg-AD brains. As shown in Figure 4b, Zn
2þ supple-




2þ) rises are toxic, Zn
2þ is
required for many physiological cell functions.
2 Zn
2þ is an
essential nutritional factor and its deﬁciency may have
important pathological consequences.
27 In that respect,
recent reports have estimated that more than 25% of the
world population is at risk of Zn
2þ deﬁciency.
28,29 In the
context of AD, however, studies on Zn
2þ deﬁciency or
supplementation in AD models have provided conﬂicting
results.
14,15,30 Here, we show thatdietary Zn
2þ supplementa-
tion prevents hippocampal-dependent cognitive deﬁcits,
reduces both intraneuronal Ab and tau pathology, prevents
mitochondrial deﬁcits and restores BDNF levels in a mouse
model of AD.
Furthermore,asthegenderdifferencehasanimportantrole




in male 3xTg-AD and PS1-KI mice in order to avoid any
confounding effect driven by female hormones.
In the last years, several lines of evidence indicate that the
accumulation of Ab in the intraneuronal compartment, more
than the extracellular space, is crucial in promoting the
amyloid pathogenic effects.
33 Our mouse model exhibits an
intraneuronalAbaccumulationinthehippocampusandcortex
that correlates with synaptic and LTP dysfunctions as well as
with the development of memory deﬁcits.
21,34 Here we show
that Zn
2þ supplementation in 3xTg-AD mice strongly reduces
the intraneuronal Ab deposition in the hippocampus but not in
the cerebral cortex.
Furthermore, recent observations describe a dose-depen-




(250mM) induce increased tau phosphorylation via glycogen
synthase kinase-3-b activation, while low-Zn
2þ concentrations






BDNF levels when compared with untreated animals. *Po0.05; **Po0.01. Error bars indicate mean values±S.E.M.
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Cell Death and Diseaseepitope. Our data strongly support this line of evidence as we
ﬁnd that 30p.p.m. (equivalent to 460mM) of Zn
2þ induces a
signiﬁcant reduction of tau phosphorylation at the thr231/
ser235 site of CA1 hippocampal pyramidal neurons. The fact
that the Zn
2þ concentration we used to feed our animals is
higher than 250mM, but still able to reduce the hippocampal
tau pathology might be explained by the ﬁltering activity of the
blood brain barrier that makes the ﬁnal Zn
2þ concentration in
the brain parenchyma likely comparable to the ‘low’ Zn
2þ
levels employed in culture studies.
Complementary to such region-speciﬁc decrease of both
Ab and tau-dependent pathology, our treatment also
completely prevents hippocampus-dependent spatial
memory deﬁcits while not affecting a cortex-dependent
cognitive test. Although the mechanisms producing these
regional differences are unknown, one possible explanation
may be associated with a distinct difference between the
hippocampus and the cortex in Ab and h-tau load.
Ourresultsarenotinaccordancewithwhatwasreportedby
Linkous et al.
14 as they found decreased amyloid plaque
deposition, but increased cognitive deﬁcits in Zn
2þ-fed
Tg2576 and TgCRND8 mice. One possible explanation for
suchdiscrepancycanberelatedtothedifferenceintheanimal
models employed in the two studies. The 3xTg-AD mice
manifest signs of Ab and tau pathology and cognitive deﬁcits
that are highly dependent on the intraneuronal deposition of
Ab
21 whereas the mice used by Linkous et al. show memory
deﬁcits mainly dependent on extracellular amyloid overload.
The different pathogenic weight of extracellular versus
intracellular amyloid deposition as well as the injurious
interaction between amyloid and tau present in the 3xTg-AD
model but not in Tg2576 and TgCRND8 mice, may likely
explain the divergent effects we report.
Energy deﬁciency and mitochondrial dysfunctions are
linked to AD, and recent ﬁndings describe the synergistic
interaction between Ab and tau in promoting OXPHOS
impairment in AD mice.
9 In line with these ﬁndings, we ﬁnd
asigniﬁcantdecayintheactivityofmitochondrial complexesI,
II and IV in the hippocampus and of complexes I and IV in the
cerebral cortex of aging 3xTg-AD mice, although no changes
are found in their cerebellum. Notably, all the mitochondrial
deﬁcits are prevented by Zn
2þ supplementation.
Tau has been shown to speciﬁcally impair mitochondrial
complex Iactivity.
9Here weshow thatcomplex Ifunctioning is
reducedinthehippocampusofaging3xTg-ADmiceandZn
2þ
rescues the complex activity in parallel with a dramatic
decrease in h-tau hippocampal immunoreactivity. In the
cerebral cortex, complex I activity shows a dramatic decrease
andsuchdeﬁcitispreventedbyZn
2þ eventhoughcorticaltau
immunoreactivity is not changed, thereby suggesting that
additional region-speciﬁc factors are playing a role in
promoting mitochondrial dysfunction in our model. Complex
II activity shows a signiﬁcant reduction in the hippocampus
while it appears to be unchanged in cortical areas, with the
exception of animals at 6m.o.a. Finally, we observe a
decrease in the activity of mitochondrial complex IV in the
hippocampus and cortex, a phenomenon that has been
previously shown to be deregulated by both Ab and tau in AD
models.
9 Our data conﬁrm these ﬁndings as we show that the
strong Ab and tau immunoreactivity we observed in these
areas goes along with a great decay of complex IV activity.
Notably, Zn
2þ-treated 3xTg-AD mice show a complete
recovery of mitochondrial complex IV activity in both the
hippocampus and cerebral cortex. Taken together, our
cortical data seem to indicate that mitochondria dysfunctions
have a partial role in promoting AD-related cognitive deﬁcits,
as simply restoring the activity of OXPHOS complexes is
per se not sufﬁcient to induce a signiﬁcant amelioration
of cognitive functions.
One possible mechanism by which Zn
2þ is beneﬁcial in our
AD model is offered by its modulation of the BDNF-tyrosine
kinase receptor type B (TrkB) receptor pathway. BDNF is
produced as a biologically inactive form (pro-BDNF) but once
converted to mature BDNF, has a pivotal role not only in
neuronal survival and differentiation, but also in maintaining
synaptic structure, function and plasticity.
35 Altered BDNF
signaling has been shown to be involved in several
neurodegenerative disorders including AD.
36 Zn
2þ induces
BDNF maturation from pro-BDNF through MMPs activation
and also transactivates synaptic TrkB by promoting Src family
kinase activity.
37 In our study, we ﬁnd a strong decrease of
BDNF levels in aging 3xTg-AD mice compared with age-
matched control mice (data not shown). Interestingly, Zn
2þ
supplementation induces a strong potentiation of MMP-2 and
MMP-9 activity that leads to a fourfold increase of BDNF
levels. Our results parallel ﬁndings of a study that employed
ZnT3-KO mice that lack synaptic Zn
2þ, show signs of
cognitive impairment and have decreased BDNF and TrkB
levels.
16 Indeed, the fact that Zn
2þ supplementation is
beneﬁcial in rescuing hippocampal dysfunctions seems to
furthersubstantiatethepivotalroleplayedbysynapticZn
2þ in
shaping the physiological neurotransmission of this crucial
brain region. The cation can critically modulate long-term
potentiation and depression by interfering with the functioning
of N-methyl-D-aspartate and g-aminobutyric acid receptors
and recent ﬁndings also indicate that Zn
2þ can act on the
ZnR, a post-synaptic metabotropic Zn
2þ-sensing receptor,
which activates MAPK and CAMK2 and ultimately affects
synaptic plasticity.
2,38 Finally, as MMPs have a role in
degrading Ab,
39,40 we can speculate that the Zn
2þ-triggered
increase of MMP activity might also exert a critical neuro-
protectiveeffectbypotentiatingtheclearanceofintraneuronal
amyloid deposits.





Animals andtreatmentparadigm. Procedures involvinganimalsand their
care were conducted in conformity with the institutional guidelines that are in
compliance with national (D.L. n. 116, G.U., suppl. 40, 18 February 1992) and
international laws and policies. All efforts were made to minimize the number of
animals used and their suffering. Transgenic mice were generated by Oddo et al.
34
and generously provided by Frank Laferla. Tap water containing zinc sulfate
(ZnSO4) was fed to 1-month-old male 3xTg-AD mice (n¼9) for a period of 11–13
months. Age-matched untreated 3xTg-AD (n¼9) or PS1-KI (n¼11) mice were
considered controls and fed with tap water. For the Zn
2þ treatment, 132mg/l of
ZnSO4 were added to tap water to reach a ﬁnal concentration of 30mg/l of Zn
2þ
(30p.p.m.). The stability of the Zn
2þ-enriched solution was veriﬁed by inductively
coupled plasma mass spectrometry.
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Cell Death and DiseaseCognitive tasks
MWM. The MWM apparatus consisted of a circular plastic tank (1.3m diameter)
ﬁlled with water. The maze was located in a room containing several intra and
extra-maze visual cues. A visible platform was employed at the beginning of the
MWM test to make sure animals had no vision deﬁcits. Mice were then trained to
swim in the tank and climb on a (12x13cm) rectangular platform submerged 2cm
beneath the surface of the water. No differences in the swimming speed were
observed between groups. To reduce the stress related to the task, mice were
placed on the platform 10s before the beginning of the ﬁrst training session. If a
mouse failed to ﬁnd the platform within 90s, it was manually guided to the platform
and allowed to remain there for 10s. Mice were placed, between trials, back into a
holding cage under a warming fan for 20min. Mice were given four trials per day for
3 consecutive days. Retention of the spatial memory task was assessed at 1.5 and
24h after the end of the last training trial. Both probe trials consisted of a 60s free
swim in the pool without the platform. The parameters measured during the probe
trial included: (1) the time (latency) spent to reach and cross the platform location
and (2) the number of crosses over the platform location. Mice were tested at
12–14m.o.a. and killed immediately after completion of the test.
NOR. Two plexiglass (30 15cm) cages were used for the whole experiment.
In the habituation phase, mice, one per cage, were placed for 15min per day for
2 consecutive days in empty cages. On day 3, the mouse was placed in a cage
containing two identical objects spaced B15cm apart and allowed to explore the
objects for 8min before returning to the home cage. To rule out innate preferences,
all the objects (made of plastic and of 5–6cm in height) were tested on mice that
werenotpartofthestudy.Objectswerewashedthoroughlywith70%ethanolbefore
each trial. On day 4, the mouse was returned to the experimental cage containing
the object to which it was previously exposed (familiar object), as well as a new
object (novel object) positioned as the day before. Mice were then allowed to
explore familiar and novel objects during a 5min-probe test that was videotaped for
subsequentanalysis.ScoringoftheNORperformancewasbasedonthetimespent
to explore both familiar and novel objects. The behavior of the mouse was
considered explorative(i.e. exploration) whentheanimalheadwaswithin1cmfrom
the object with the neck extended and vibrissae moving.Simple proximity, chewing,
or standing on the object did not count as exploration. Novel object exploration was
calculated, as percentage,applying the following formula: [A/(AþB)] 100, where
Ais thetimespentto explorethenovelobject andB isthetimespenton the familiar
one.AswiththeMWMtest,miceweretestedat12–14m.o.a.andkilledimmediately
after completion of the test.
Brain tissue preparation. Mice were killed by carbon dioxide inhalation, and
brains rapidly taken after removal of cerebellum and sagittally halved. One
hemisphere and the cerebellum were frozen in liquid nitrogen and stored at –801C
untiluse for further western blottinganalysis,theother hemispherewas included for
24–36hatroomtemperature(RT)inCarnoyﬁxativesolution(65%ethanoland35%
chloroform) and eventually processed for immunohistochemistry. In the case of
BN-PAGEanalysis,brains were quickly dissected on ice and the cerebellum, cortex
and hippocampus immediately frozen on dry ice and stored at  801C.
Immunoblotting. Tissuesampleswerehomogenizedinanice-coldlysisbuffer
(50mM Tris-HCl, pH 8, 150mM NaCl, 0.1% SDS, 0.5mM sodium orthovanadate, 1mM
sodium ﬂuoride and 1% Triton X-100) supplemented with a cocktail of protease and
phosphatase inhibitors (Sigma-Aldrich, St Louis, MO, USA). The homogenates were
brieﬂy sonicated and then centrifuged at 41C for 30min at 14000r.p.m. The supernatant
was used for immunoblot analysis. Protein concentration was determined using the
Bradford method (Bio-Rad, Hercules, CA, USA). In all, 60–80mg of proteins was resolved
by SDS-PAGE (8–12% Bis-Tris from Sigma-Aldrich) under reducing conditions and
transferred to a nitrocellulose membrane. The membrane was incubated in Tris-buffered
saline and Tween 20 (TBST) containing 5% of nonfat dry milk for 1h at 201C. After an
overnight incubation at 41C in TBST with the primary antibody, blots were washed for
30min, incubated for an additional hour at 201C with the secondary antibody and ﬁnally
developed using the ECL PLUS (GE Healthcare, Little Chalfont, UK) chemiluminescence
system. Bands were quantiﬁed by densitometry using NIH- Image J 1.61 (public domain
software).
Antibodies. The following antibodies were used: anti-Ab, clone DE2B4, diluted
1:400 (Abcam, Cambridge, MA, USA); anti-phosphoTau AT180 1:400 (Pierce,
Rockford, IL, USA); anti-b-actin 1:10000 (Sigma-Aldrich) and anti-BDNF, 1:1000
(Cell Signaling, Beverly, MA, USA). Secondary ECL antibodies both anti-mouse and
anti-rabbit (GE Healthcare) peroxidase linked were also used.
Immunohistochemistry. Carnoy-ﬁxed and parafﬁn embedded brains were
sagittaly sectioned (n¼5per group).Sectionswerenot pretreatedwith formic acid.
Antigen retrieval was performed by microwave treatment at 750 W for 10min in a
10mmol/l sodium citrate buffer (pH 6.0). After blocking the endogenous mouse IgG
antibodies (Biocare Medical, Concord, CA, USA), sections were incubated
overnight with the primary antibody. Slices were then incubated with the
secondary anti-mouse (HRP-polymer EnVision kit, Dako, Glostrup, Denmark),
counterstained with Mayer’s hematoxylin and the reaction visualized using
diamminobenzidine as chromogen. Images of h-tau and Ab stained sections
were acquired using a 100  (for Ab) or 200  (for h-tau) magniﬁcations with a
Leica DMR microscope (Leica Microsystems GmbH, Wetzlar, Germany) equipped
with a DMR 500 digital camera (Leica). The number of stained pyramidal neurons
and neuroﬁbrillary tangles was measured using Photoshop 8.0 (Adobe Systems
Incorporated, San Jose, CA, USA) by using the Photoshop Lasso Tool and pixel
numbers obtained from the resulting histogram. After this ﬁrst step, we used the
Magic Wand tool to select a representative positive cell signal. All the
immunostained cells were automatically selected and the total pixel number
recorded. Pixel counts were normalized to a hippocampal area of 1mm.
2
BN-PAGE on mitochondrial samples. After solubilization of
mitochondrial membranes by dodecyl maltoside, 20mg of each sample was
loadedona6–13%gradientacrylamidegelandsubjectedtoelectrophoresisonice.
For each set of gels, one gel was stained with Coomassie blue and the second one
used to determine enzymatic activities. Complex I (NADH-dehydrogenase) activity
was determined by incubating the gel with 0.1M Tris-HCl, 768mM glycine, 0.1mM
b-NADHand0.04%nitrobluetetrazoliumatpH7.4andRT.Asanindexofcomplex
II activity,we evaluatedsuccinate dehydrogenaseactivity incubatingthegelin 0.1M
Tris–HCl, 100mMglycine,10mM succinic acid and1mg/ml NTBat pH 7.4 andRT.
Complex IV (COX) activity was estimated by incubating BN-PAGE gels with 5mg
3,30-diaminobenzidine tetrahydrochloride (DAB) dissolved in 9ml phosphate buffer
(0.05M, pH 7.4), 1ml catalase (20mg/ml), 10mg cytochrome C and 750mg
sucrose.
Violet-colored complex I and II bands and red-stained complex IV were
measured using the Bio-Rad Imaging Densitometer (GS-800, Bio-Rad). Band
intensities were expressed as absolute values in arbitrary units. The optical density
(OD) of each band was plotted against the OD value derived from the Coomassie
blue gel.
Gelatine zymography. SDS-PAGE gels (7.5%) were prepared with 0.1%
gelatin incorporated during polymerization. In all, 50mg of proteins was loaded on
gel lanes and ﬁnally subjected to electrophoresis on ice at 40mA constant in
non-denaturing conditions. After electrophoresis, SDS was removed from gels by
washing twice with a renaturating buffer (50mM Tris-HCl, pH 7.4, and 2.5% Triton
X-100) for 20min each.Gels werethenincubatedovernightat 371Cin an activation
buffer (50mM Tris-HCI, pH 7.4, 120mM NaCl, 5mM CaCl and 0.04% NaN3).
Following the incubation, gels were stained for 30min with 0.1% Coomassie blue
(dissolved with 40% methanol and 10% acetic acid) and destained in the same
solution without Coomassie until clear proteolytic bands appeared on the
contrasting blue background. Bands were quantiﬁed by densitometry using
NIH- Image J 1.61.
Statistics. For western blotting experiments, immunohistochemistry and novel
object recognition test, statistical differences were determined with the Student’s
t-test for unpaired data. For analysis of the MWM latencies and BN-PAGE
experiments, the homogeneity of the variances was determined by the Bartlett test
(90% conﬁdence level) and a one-way ANOVA was performed followed by a
post-hoc Bonferroni’s correction.All dataare expressed asmean±S.E.M.Analysis
of the MWM crosses number employed the non-parametric Kruskal–Wallis test and
the threshold for statistically signiﬁcant differences was set at Po0.05.
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